Published in J Virol on October 01, 2002
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol (2004) 4.12
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol (2006) 3.20
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol (2006) 2.48
Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol (2003) 2.40
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames. J Exp Med (2004) 1.48
Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38
Infection of hematopoietic progenitor cells by HIV-1 subtype C, and its association with anemia in southern Africa. Blood (2007) 1.28
Characterization of Nef-CXCR4 interactions important for apoptosis induction. J Virol (2004) 1.24
Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol (2005) 1.15
Evolution of proviral gp120 over the first year of HIV-1 subtype C infection. Virology (2008) 1.14
CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol (2006) 1.13
An integrative bioinformatic approach for studying escape mutations in human immunodeficiency virus type 1 gag in the Pumwani Sex Worker Cohort. J Virol (2007) 1.10
Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India. J Clin Microbiol (2004) 1.09
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol (2009) 1.07
Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol (2004) 1.06
Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest (2007) 1.06
Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol (2008) 1.03
Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol (2008) 1.02
Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine (2007) 0.96
APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet (2012) 0.95
Elimination of helminth infection restores HIV-1C vaccine-specific T cell responses independent of helminth-induced IL-10. Vaccine (2009) 0.93
Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. J Virol (2005) 0.92
Recognition of HIV-1 peptides by host CTL is related to HIV-1 similarity to human proteins. PLoS One (2007) 0.92
Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood (2009) 0.89
CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins. Virology (2004) 0.88
Apoptotic peptides derived from HIV-1 Nef induce lymphocyte depletion in mice. Ethn Dis (2008) 0.86
A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection. J Virol (2007) 0.86
Preferential CTL targeting of Gag is associated with relative viral control in long-term surviving HIV-1 infected former plasma donors from China. Cell Res (2012) 0.85
Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection. PLoS One (2012) 0.84
Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses. Virology (2005) 0.83
Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection. PLoS One (2008) 0.83
Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection. Clin Diagn Lab Immunol (2005) 0.83
Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC). Retrovirology (2007) 0.81
Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS One (2014) 0.80
Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections. J Virol (2014) 0.79
tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. J Virol (2013) 0.79
A comprehensive analysis of the naturally occurring polymorphisms in HIV-1 Vpr: potential impact on CTL epitopes. Virol J (2008) 0.79
Intra- and intersubtype alternative Pak2-activating structural motifs of human immunodeficiency virus type 1 Nef. J Virol (2006) 0.79
Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood. Clin Diagn Lab Immunol (2005) 0.78
A Generalized Entropy Measure of Within-Host Viral Diversity for Identifying Recent HIV-1 Infections. Medicine (Baltimore) (2015) 0.76
Comparing the similarity of different groups of bacteria to the human proteome. PLoS One (2012) 0.76
Group M consensus Gag and Nef peptides are as efficient at detecting clade A1 and D cross-subtype T-cell functions as subtype-specific consensus peptides. Vaccine (2014) 0.75
Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals. Med Microbiol Immunol (2008) 0.75
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41
Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol (1999) 7.18
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol (1998) 3.65
Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest (1998) 3.53
Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr (2002) 3.40
Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol (1999) 2.90
Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (1991) 2.83
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66
Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). Mol Biol Evol (1995) 2.51
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses (2001) 2.23
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A (2001) 1.94
Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Res Hum Retroviruses (1996) 1.92
Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol (2002) 1.91
Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol (1995) 1.91
Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol (1997) 1.90
Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol (2001) 1.82
Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol (2000) 1.79
Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc Natl Acad Sci U S A (1998) 1.74
The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol (1999) 1.72
Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone. J Virol (2001) 1.70
Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses (1999) 1.69
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64
Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol (2001) 1.63
Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. J Virol (1999) 1.61
Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.61
Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol (1997) 1.60
Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol (2001) 1.57
Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet (2000) 1.57
HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS (1999) 1.55
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol (1997) 1.45
Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine (2001) 1.38
Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS (1998) 1.35
Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med (2000) 1.35
Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol (1993) 1.33
Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design. Hum Immunol (2001) 1.25
Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses (2001) 1.23
Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol (2000) 1.23
Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol (1999) 1.20
Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol (1998) 1.18
Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A (1995) 1.17
Th1 T cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J Immunol (1999) 1.14
AIDS vaccine development in primate models. AIDS (1998) 1.12
Immunodominance in T lymphocyte recognition. Immunol Lett (1988) 1.12
Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine (1999) 1.11
Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J Virol (2001) 1.08
Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. Virology (2000) 1.07
Hierarchies of antigen-specific cytotoxic T-cell responses. Immunol Rev (1998) 1.06
The role of nonhuman primates in the development of an AIDS vaccine. AIDS (1999) 1.06
Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues. J Immunol (1995) 1.03
Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses. AIDS (2002) 1.02
Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses (1998) 1.01
Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes. J Immunol (1996) 1.00
Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J Virol (2000) 0.97
Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis (2000) 0.97
Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J Hum Virol (2001) 0.96
Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens. Vaccine (1998) 0.94
Conservation of cytotoxic T lymphocyte (CTL) epitopes as a host strategy to constrain parasite adaptation: evidence from the nef gene of human immunodeficiency virus 1 (HIV-1). Mol Biol Evol (1998) 0.93
Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol Lett (2001) 0.93
Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine (1999) 0.93
A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retroviruses (1998) 0.93
Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. AIDS Res Hum Retroviruses (1999) 0.93
Identification of multirestricted immunodominant regions recognized by cytolytic T lymphocytes in the human immunodeficiency virus type 1 Nef protein. J Virol (1994) 0.92
The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. Vaccine (1997) 0.90
Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J Virol (2001) 0.89
Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine (1993) 0.89
Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses (2001) 0.88
Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine (2001) 0.88
Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res Hum Retroviruses (1997) 0.88
The role of nonhuman primate models in AIDS vaccine development. Mol Med Today (2000) 0.87
Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. J Biotechnol (1996) 0.86
Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. J Virol (1995) 0.85
A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. Vaccine (1999) 0.85
Increased promoter diversity reveals a complex phylogeny of human immunodeficiency virus type 1 subtype C in India. J Hum Virol (2000) 0.84
Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice. J Virol (1997) 0.81
Induction of T cell responses by chimeric bacterial proteins expressing several copies of a viral T cell epitope. Eur J Immunol (1993) 0.81
New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design. AIDS (1999) 0.80
Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response. Gene Ther (2001) 0.77
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08
Does housestaff discontinuity of care increase the risk for preventable adverse events? Ann Intern Med (1994) 10.29
Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science (1985) 9.27
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Cyclin activation of p34cdc2. Cell (1990) 6.87
Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med (2010) 6.38
Contaminant blood cultures and resource utilization. The true consequences of false-positive results. JAMA (1991) 6.28
RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell (1995) 5.73
Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell (1986) 5.35
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Male circumcision: an acceptable strategy for HIV prevention in Botswana. Sex Transm Infect (2003) 5.26
Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J Antimicrob Chemother (1988) 5.10
A mutation in Arabidopsis that leads to constitutive expression of systemic acquired resistance. Plant Cell (1994) 4.88
Physician reporting compared with medical-record review to identify adverse medical events. Ann Intern Med (1993) 4.60
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med (2000) 4.14
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
Extended high viremics: a substantial fraction of individuals maintain high plasma viral RNA levels after acute HIV-1 subtype C infection. AIDS (2011) 3.95
Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol (1997) 3.93
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science (1985) 3.74
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Sequence motifs and free energies of selected natural and non-natural nucleosome positioning DNA sequences. J Mol Biol (1999) 3.72
Diabetes mellitus: induction in mice by encephalomyocarditis virus. Science (1968) 3.67
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Sensitivity of biofilms to antimicrobial agents. J Appl Bacteriol (1993) 3.39
Assessment of operative risk in patients undergoing lung resection. Importance of predicted pulmonary function. Chest (1994) 3.31
Predicting bacteremia in hospitalized patients. A prospectively validated model. Ann Intern Med (1990) 3.31
Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape. J Cell Biol (2000) 3.30
Plants and animals share functionally common bacterial virulence factors. Proc Natl Acad Sci U S A (2000) 3.21
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Antigens encoded by the 3'-terminal region of human T-cell leukemia virus: evidence for a functional gene. Science (1984) 3.20
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
A functional link between dynamin and the actin cytoskeleton at podosomes. J Cell Biol (2000) 3.12
Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science (1994) 3.10
Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem (1991) 3.06
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med (1995) 3.03
Rapid classification of positive blood cultures. Prospective validation of a multivariate algorithm. JAMA (1992) 3.02
Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med (1993) 3.00
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr (2008) 2.93
Feline oncornavirus-associated cell membrane antigen: evidence for an immunologically crossreactive feline sarcoma virus-coded protein. Proc Natl Acad Sci U S A (1977) 2.93
Heterogeneity of therapeutic responses in asthma. Br Med Bull (2000) 2.86
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
The dynamin family of mechanoenzymes: pinching in new places. Trends Biochem Sci (2000) 2.75
Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm. J Bacteriol (2004) 2.74
Role of dynamin in the formation of transport vesicles from the trans-Golgi network. Science (1998) 2.71
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses (1990) 2.67
Iterative methods for the three-dimensional reconstruction of an object from projections. J Theor Biol (1972) 2.66
Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J Virol (1990) 2.60
Natural protection against HIV-1 infection provided by HIV-2. Science (1995) 2.54
The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol (1992) 2.51
Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room. Am J Cardiol (1987) 2.50
Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science (1983) 2.48
Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One (2010) 2.48
Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa. Lancet (1986) 2.48
Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms towards ciprofloxacin: effect of specific growth rate. J Antimicrob Chemother (1991) 2.47
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax (1997) 2.46
Extracellular products as mediators of the formation and detachment of Pseudomonas fluorescens biofilms. FEMS Microbiol Lett (1998) 2.46
A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med (1988) 2.46
Slower heterosexual spread of HIV-2 than HIV-1. Lancet (1994) 2.46
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Patient and house officer attitudes on physician attire and etiquette. JAMA (1987) 2.44
Identification and characterization of genomic nucleosome-positioning sequences. J Mol Biol (1997) 2.41
Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol (2003) 2.40